ARIUS announces cancer stem cell antibody program successfully completes first toxico...( Toxicology and pharmacokinetics of chim...)

Efficacy Presentation

ARIUS' CD44 targeting antibody has demonstrated significant tumor growth inhibitory activity in in vivo animal models of breast, prostate, liver, and AML cancers. In breast cancer models, the antibody demonstrated tumor regression with increased survival at all doses. Two humanized versions of the antibody have been generated and their affinity is comparable to that of the chimeric and murine antibodies. The results of this study have also demonstrated the potential for the antibody to target the cancer stem cell antigen in breast cancer. The potency of the two humanized antibodies on tumor growth inhibition has been demonstrated in established tumor models in preparation for human clinical trials in 2008.

Additional information can be found at AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics in San Francisco at the following location and times: Abstract A74: "Chimeric and humanized versions of the anti-CD44 monoclonal antibody ARH460-16-2 have potent anti-tumor efficacy in established models of human breast and metastatic liver cancer." Session A, Tuesday, October 23, 2007, between 12:30-2:30 p.m. and 5:30-7:30 p.m.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the
'/>"/>